Search Results
Your search for The ASCO Post matches 17125 pages
Showing 2151 - 2200Study Identifies Potential Molecular Differences Between Primary Breast Cancer and Its Metastases
Researchers have identified unique molecular features responsible for the development and progression of metastatic breast cancer, according to a novel study published by Garcia-Recio et al in Nature Cancer. They discovered that one of the key features involves changes in the immune system that are ...
Study Investigates Burden of Cervical Cancer Among Patients Aged 65 and Older
Researchers discovered that a significant number of patients aged 65 years and older may be facing late-stage cervical cancer diagnoses and disease-related mortality—despite U.S. Centers for Disease Control and Prevention (CDC) guidelines recommending that most patients stop screening for cervical...
Novel Therapy Afamitresgene Autoleucel Shows Early Potential for Antitumor Activity
The adoptive T-cell receptor therapy afamitresgene autoleucel—which targets the MAGE-A4 cancer antigen—achieved clinically significant results for patients with multiple solid tumor types in a phase I clinical trial, according to a novel study published by Hong et al in Nature Medicine. Initial...
Addition of Apalutamide May Slow Progression of Early-Stage Prostate Cancer During Active Surveillance
For patients with early-stage prostate cancer being managed by active surveillance, adding the hormonal agent apalutamide may lower the rate of positive biopsies during follow-up, suggest findings from a preliminary clinical trial published by Schweizer et al in The Journal of Urology. "In our...
Delaying Antibiotics May Not Affect Overall Survival Among Inpatients With Cancer Who Have Neutropenic Fever
Among inpatients with cancer who have neutropenic fever, delaying antibiotic treatment past 60 minutes from the time of fever detection may not reduce the short-term chance of overall survival, according to a new study published by Villars et al in the American Journal of Medical Quality....
Immune System B Cells May Help to Predict Treatment Response Among Patients With HER2-Positive Breast Cancer
Researchers have found that measuring the activation of immune system B cells may be more effective than measuring the activation of either T cells or tumor-infiltrating lymphocytes (TILs) in predicting whether patients with HER2-positive breast cancer will respond to treatment. These findings were ...
New AI-Based Biomarker May Help Predict Immunotherapy Response for Patients With NSCLC
Researchers have discovered a new artificial intelligence (AI)-derived biomarker that uses routine imaging scans to help predict which patients with non–small cell lung cancer (NSCLC) will respond to immunotherapy, according to a novel study published by Alilou et al in Science Advances. The...
Prostate Cancer Screening Among Primary Care Providers
Investigators recently examined prostate cancer screening among primary care providers and found that screening tests were frequently used—even when they provide little value to patients, according to a new study published by Gillette et al in the Journal of the American Board of Family Medicine....
FoundationOne Liquid CDx Receives FDA Approval as a Companion Diagnostic for Entrectinib
On January 4, the U.S. Food and Drug Administration (FDA) approved FoundationOne Liquid CDx to be used as a companion diagnostic to identify patients with ROS1-positive non–small cell lung cancer (NSCLC) or NTRK fusion–positive solid tumors who do not have a tissue sample available and may be...
Mitomycin Gel for Upper Tract Urothelial Cancers: Postmarket Analysis
Researchers have performed the first postmarkert analysis of a novel delivery system of mitomycin—a gel formation, also known as UGN-101—to treat upper tract urothelial cancers, according to a novel study published by Woldu et al in Urologic Oncology. Their findings showcase how the treatment is...
EMERALD Trial: Elacestrant vs Standard Endocrine Monotherapy for Advanced Breast Cancer After CDK4/6 Inhibition
Elacestrant—an investigational oral selective estrogen receptor degrader (SERD)—achieved longer progression-free survival vs standard-of-care endocrine monotherapy as second- or third-line therapy in patients with estrogen receptor–positive, HER2-negative advanced or metastatic breast cancer in the ...
Phase III IMerge Trial of Imetelstat in Lower-Risk MDS
Positive results were announced from the phase III IMerge trial (ClinicalTrials.gov identifier NCT02598661) evaluating the first-in-class telomerase inhibitor imetelstat in patients with lower-risk myelodysplastic syndromes (MDS) who are relapsed, refractory, or ineligible for...
World Cancer Day 2023: February 4
World Cancer Day 2023 is now only 1 month away! Led by the Union for International Cancer Control (UICC) and organized annually on February 4, World Cancer Day is a global initiative to improve awareness and knowledge of cancer risks and better prevent, detect, and treat the disease. World Cancer...
Updated Data From a Phase II Trial of Triplet Therapy in HPV-Positive Cancers
Expanded interim data from a phase II clinical trial investigating PDS0101-based triple combination therapy in advanced human papillomavirus (HPV)-positive cancers were recently announced. The triple combination of PDS0101—a novel T-cell HPV-specific immunotherapy—with the tumor-targeting IL-12...
Triple Immunotherapy Combination Studied Preclinically for Pancreatic Cancer
Researchers at The University of Texas MD Anderson Cancer Center have discovered a novel immunotherapy combination, targeting checkpoints in both T cells and myeloid suppressor cells, that successfully reprogrammed the tumor immune microenvironment and significantly improved antitumor responses in...
Study Compares the Cost and Efficacy of Anticoagulant Therapies
Research conducted by UC Davis Comprehensive Cancer Center and the University of Cincinnati showed that direct oral anticoagulants (DOACs) are more effective—and more cost-effective—than low–molecular-weight heparin for treating cancer-associated thrombosis. A study published by Gulati et al in...
One in Seven Diagnosed Cancers Is Found by Recommended Screening Tests
Despite widespread awareness of the importance of screening for asymptomatic, early detection of cancer, screening tests exist for only five cancer types. With few recommended cancer screening tests and generally low adherence to cancer screening recommendations, it is difficult to detect cancer...
Study Examines ‘Reconstructive Burnout’ Phenomenon: Patients Who Start Breast Reconstruction After Mastectomy but Don't Complete It
Nearly one-fourth of patients with breast cancer who start breast reconstruction after mastectomy don't complete the reconstructive process. The concept of reconstructive burnout was introduced and discussed in a study published by Halani et al in the January issue of Plastic and Reconstructive...
FDA Approves Mosunetuzumab-axgb, a First-in-Class Bispecific Antibody, in Relapsed or Refractory Follicular Lymphoma
On December 22, the U.S. Food and Drug Administration (FDA) approved mosunetuzumab-axgb (Lunsumio) for the treatment of adults with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. Mosunetuzumab-axgb is a CD20/CD3 T-cell–engaging bispecific antibody and...
Sotorasib Shows Clinically Meaningful Activity Among Patients With KRAS G12C–Mutated Advanced Pancreatic Cancer
The KRAS G12C inhibitor sotorasib demonstrated clinically meaningful anticancer activity with an acceptable safety profile in heavily pretreated patients with KRAS G12C–mutated metastatic pancreatic cancer, accordi�ng to a novel study published by Strickler et al in The New England Journal of...
Study Examines Genitourinary Cancer Trends, Disparities in the United States
New findings revealed that the highest mortality rates for prostate cancer among White male patients were found in the Western United States—including California—despite low incidence rates, according to a new study published by Schafer et al in European Urology. However, when compared with White...
Barbara Burtness, MD, Named Chief Translational Research Officer for Yale Cancer Center and Smilow Cancer Hospital
Barbara Burtness, MD, Professor of Medicine (Medical Oncology), has been named Chief Translational Research Officer for Yale Cancer Center and Smilow Cancer Hospital and Associate Cancer Center Director for Translational Research for Yale Cancer Center. Dr. Burtness’ experience, leadership, and...
Eyal Gottlieb, PhD, to Join MD Anderson as Vice President for Research
The University of Texas MD Anderson Cancer Center recently announced that Eyal Gottlieb, PhD, has been named the institution’s Vice President for Research. In this role, Dr. Gottlieb will oversee laboratory science departments leading innovative discovery and translational research across a variety ...
Chronic Myelomonocytic Leukemia: Treatment and Prognosis, Part 2
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In the concluding half of this two-part installment, which began in our November 25 issue, Drs. Syed Ali Abutalib and Mrinal M. Patnaik continue to explore the current...
How ASCO and the Oncology Community Came Together to Discuss Progress in Global Cancer Control and the Challenges Ahead
After a 4-year in-person hiatus because of the COVID-19 global pandemic, the World Cancer Congress, hosted by the Union for International Cancer Control (UICC), held its first hybrid in-person and virtual meeting in October in Geneva. The conference brought together more than 2,000 attendees from...
World Cancer Research Fund International Launches New Flagship Research Program
The cancer prevention and survival research organization World Cancer Research Fund (WCRF) International recently launched the Global Cancer Update Programme, a new and updated version of the organization’s flagship research program, which was previously known as the Continuous Update Project. This ...
Expert Point of View: Rimas V. Lukas, MD
Rimas V. Lukas, MD, a neuro-oncologist at Northwestern Medicine Lou and Jean Malnati Brain Tumor Institute, Chicago, praised the investigators’ willingness to explore relatively new areas of cancer research. “This is an interesting study by a strong group delving further into the nervous...
Expert Point of View: Ryan J. Sullivan, MD
Ryan J. Sullivan, MD, Associate Professor of Medicine at Harvard Medical School, and Associate Professor of Hematology/Oncology at Massachusetts General Hospital, Boston, told The ASCO Post that tumor-infiltrating lymphocyte (TIL) cell therapy is likely to become a standard practice in the field....
Research Exposes Inequities in Health-Care Access and Delivery for Blood Disorders
Several studies presented during the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition uncovered significant disparities in medical care and health outcomes among patients of different racial backgrounds, nationalities, and socioeconomic status across a range of blood...
How Telemedicine Can Transform Clinical Research and Practice
The COVID-19 pandemic transformed the world, and nowhere more so than in the health-care arena. Significant changes happened almost overnight in the delivery of medical care to focus on the safety and convenience of patients, staff, and providers. Although pilot efforts to integrate telemedicine...
How the American Cancer Society Aims to Improve Outcomes in Breast and Cervical Cancers and Reduce Health Disparities
Just days before the publication of the 2022 Annual Report to the Nation on the Status of Cancer on October 27, 2022,1 which showed a continued downward trend in cancer deaths, Karen Knudsen, MBA, PhD, Chief Executive Officer of the American Cancer Society (ACS), joined the First Lady Dr. Jill...
Expert Point of View: Aditya Bardia, MD, MPH
Aditya Bardia, MD, MPH, Director of Breast Cancer Research and Associate Professor at Harvard Medical School, and attending physician at Mass General Cancer Center, Boston, commented on the RIGHT Choice trial. Based on this study, he noted, few patients should be excluded from treatment with...
Study Finds Medicaid Expansion May Improve Survival Outcomes for Young Adult Patients With Cancer
Researchers have discovered that expanded Medicaid coverage under the Affordable Care Act may lead to better survival outcomes for young adult patients aged 18 to 39 years who have been newly diagnosed with cancer—particularly among those who identify as Hispanic or non-Hispanic Black—according to...
Quantifying the Population, Clinical, and Scientific Impact of NCTN Research
Clinical trials involving adult patients conducted within the National Cancer Institute’s National Clinical Trials Network (NCTN) over the past 4 decades are estimated to have extended the lives of U.S. patients with cancer by at least 14.2 million patient-years, according to a new study published...
FDA Approves FoundationOne Liquid CDx as a Companion Diagnostic for a Certain Group of Tyrosine Kinase Inhibitors
On December 21, Foundation Medicine, Inc, announced that the U.S. Food and Drug Administration (FDA) approved its FoundationOne Liquid CDx as a companion diagnostic to identify patients with non–small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions or exon 21 L858R substitutions...
2022 San Antonio Breast Cancer Symposium Award Recipients Announced
The San Antonio Breast Cancer Symposium (SABCS) and the American Association for Cancer Research (AACR), an SABCS cosponsor, honored two researchers for their significant contributions to breast cancer research at the 2022 SABCS. 2022 AACR Distinguished Lectureship in Breast Cancer Research Charles ...
2021 JADPRO Article of the Year Award Spotlights Management of Adverse Events in Immunotherapy
A team of advanced practice providers in the Department of Hematology/Oncology at Fox Chase Cancer Center have received the 2021 Article of the Year Award from the Journal of the Advanced Practitioner in Oncology (JADPRO). This award is given to one article each year that demonstrates an...
MD Anderson and WHO Establish a New International Collaboration to Reduce the Global Burden of Women’s Cancers
The University of Texas MD Anderson Cancer Center and the World Health Organization (WHO) recently announced a formal agreement to establish a new international collaboration concentrated on reducing the global burden of women’s cancers. The agreement builds on years of collaboration between the...
Cedars-Sinai Cancer Leaders Assume New Roles
Lali Medina-Kauwe, PhD, former Co-Leader of the Cancer Biology Program in Cedars-Sinai Cancer, assumed a new role as Associate Director for Basic Research. The Cancer Biology Program will now be led by Dolores Di Vizio, MD, PhD, Professor of Biomedical Sciences, Pathology and Laboratory Medicine in ...
How Do You Move Forward With a Life You Didn’t Choose After a Cancer Diagnosis?
“I was in bed in the surgical wing of Duke University Hospital when the doctor popped his head in and smiled apologetically before flicking on the fluorescent lights. It was 4:00 AM, the end of my second night in the hospital, but nobody sleeps in the conventional sense,” writes Kate Bowler in the...
Fox Chase Receives $6 Million Grant as Founding Member of New NCI Prevention Initiative
Fox Chase Cancer Center was recently awarded a grant for $6 million over the course of 5 years to develop a new Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT). The new National Cancer Institute (NCI) program was created to establish a pipeline for the discovery of new...
New Approaches Still Needed to Treat Patients With Cancer Who Have Serious Mental Illness
Although mandates by ASCO and the American Cancer Society to meet the needs of underserved populations have drawn much-needed awareness to the issue, patients with cancer who experience bipolar disorder, schizophrenia, and other debilitating mental illnesses continue to experience significantly...
FDA Approves Pafolacianine to Aid Lung Cancer Surgery
The U.S. Food and Drug Administration (FDA) has approved the targeted imaging agent pafolacianine (Cytalux) for use in lung cancer surgery. This injectable diagnostic binds to cancerous tissue and glows when stimulated by near-infrared light, making it easier for surgeons to remove tumors...
A Serendipitous Ride Along a Highway May Have Saved My Life
In 2017, I noticed a roadside billboard touting the benefits of low-dose computed tomography (CT) imaging for lung cancer screening. The message probably saved my life. The public service campaign, called Saved by the Scan from the American Lung Association, included an Internet address where I...
Sidney Kimmel Cancer Center Establishes Geriatric Oncology Center of Excellence at Jefferson Health
Jefferson Health’s Sidney Kimmel Cancer Center (SKCC) recently launched the Geriatric Oncology Center of Excellence to address the needs of a growing patient population through innovative research and care delivery methods via a multidisciplinary approach. The center identifies and removes barriers ...
Traditional Chinese Medicine Herbal Formula Shen Ling Bai Zhu San for Chronic Diarrhea
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Yen Nien (Jason) Hou, PharmD, DiplOM, LAc, and Jyothirmai Gubili, MS, focus on ...
Robin Zon, MD, FACP, FASCO, Elected ASCO President for 2024–2025 Term
ASCO has elected Robin Zon, MD, FACP, FASCO, a long-time member and volunteer, to lead as its President beginning in June 2024. Dr. Zon will take office as President-Elect immediately following the ASCO Annual Business Meeting in Chicago on June 5, 2023. Five additional members were also elected to ...
Risk of Adverse Side Effects From Cancer Immunotherapy May Be Higher in Patients With Certain Inherited Genetic Variations
Even as they’ve revolutionized cancer treatment, immune checkpoint inhibitors have been shown to produce a range of adverse immune-related side effects. Researchers have now identified inherited genetic variations that may place patients at high risk for complications when undergoing treatment with ...
Understanding the Health Provisions in the Inflation Reduction Act and Their Implications for Oncology Care
The Inflation Reduction Act of 2022, signed into law on August 16, 2022, contains several important provisions regarding health care and drug pricing.1 In this article, I provide an overview of the legislation’s implications for oncology care, focusing on its provisions concerning drug price...
Indiana University Names Music Therapy Researcher Sheri Robb, PhD, as New Walther Professor of Supportive Oncology
Indiana University (IU) School of Medicine has named Sheri Robb, PhD, a Walther Professor of Supportive Oncology. This is one of five endowed positions to develop a supportive oncology program that encompasses research and patient care. Dr. Robb is a nationally renowned music therapy researcher,...
